Latest Trends

Global Cord Blood Corporation Investors Alerted to Lead Plaintiff Deadline in Securities Class Action Lawsuit

NEW YORK, May 20, 2024 /PRNewswire/ -- The esteemed Rosen Law Firm is reminding individuals who purchased securities from Global Cord Blood Corporation (NYSE: CO) (OTC: CORBF) between June 4, 2019, and May 3, 2022, of the pressing June 24, 2024 deadline to apply as a lead plaintiff in a pivotal class action lawsuit.

Investors Entitled to Compensation

For those who have invested in Global Cord securities during the designated Class Period, you may be in line to receive restitution that doesn't involve any out-of - pocket fees or costs due to a contingency fee arrangement. This provides investors a chance to claim their rightful compensation without taking on financial risk in terms of legal costs.

Participation and Legal Representation

To become a member of the Global Cord class action, simply visit Rosen Legal's Case Submission Form or reach out directly to Phillip Kim, Esq. by calling toll-free at 866-767-3653 or emailing [email protected] for more detailed information regarding the lawsuit. In the event that you are inclined to serve as lead plaintiff, it is imperative that you move the Court expeditiously, as the steps to file a motion must be undertaken no later than June 24, 2024. It is of utmost importance to note that the lead plaintiff position is not merely symbolic; it is a role of substantial responsibility wherein the appointed individual will act on behalf of other class members in the guidance of the litigation process.

A History of Success: The Rosen Law Firm

Choosing qualified and competent legal counsel is a critical factor for investors. This is elaborated by the unsettling fact that some firms, although they issue notices to potential litigants, might not possess equivalent experience, resources, or be acknowledged among their peers in the legal community. These firms may not actively engage in securities class actions, instead operating as intermediaries that refer clients or collaborate with law firms who actually argue the cases. The Rosen Law Firm, however, prides itself on representing investors internationally, with a concentrated expertise in securities class actions and shareholder derivative litigation. Notably, the firm attained the largest securities class action settlement ever against a Chinese Company and has been consistently ranked in the top 4 each year since 2013 by ISS Securities Class Action Services. The firm achieved over $438 million in investor recoveries in 2019, spotlighting its dedication to serving its clients' interests. In addition, founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by law360 in 2020, validating the professional eminence of the firm’s legal team.

Allegations of Fiduciary Misconduct

The lawsuit contends that throughout the Class Period, defendants engaged in the dissemination of false and/or misleading statements and did not disclose critical information, leading to significant investor detriment. The case details the allegations that the capital allocation strategy deployed by Global Cord Blood Corporation was fundamentally skewed in favor of company insiders and related parties, thereby disadvantaging the shareholders. It is alleged that numerous declined private purchase offers and the decision to pursue the Transaction, an over $1 billion agreement to acquire Cellenkos Inc., were based on the individual vested interests of the defendants rather than potential benefits for the shareholders. This purported self-serving conduct included dealings by defendant Yuen Kam and his associated entities, which were painted as strategic investments and transactions within the company's public communication. However, the lawsuit alleges that in truth, these were orchestrated to misappropriate hundreds of millions of dollars from the company.

The Financial Repercussions of Disclosure

Investors allegedly suffered significant monetary damages due to the erroneous and potentially deceptive public statements issued by Global Cord Blood Corporation. When the actual situation was disclosed to the public domain, it triggered a substantial negative impact on the trust and financial standing of the company amongst the investment community. The complaint argues that the information, which was eventually unveiled, nullified previous company statements and led to considerable losses for the investors, who had been misled.

Steps Forward for Affected Investors

Investors who believe they were impacted by these actions of Global Cord Blood Corporation and wish to participate in the class action must act promptly by again visiting Rosen Legal's Case Submission Form. Alternatively, for personal guidance and insight into the proceedings, individuals can contact Phillip Kim, Esq. through the toll-free number or by email. It is a vital crossroads for investors, as a decision to seek legal recourse could lead to recovery of their losses.

Understanding Class Certification

It is critically important for investors to understand that at this stage, no class has been certified, meaning there is no formal representation by counsel unless one personally retains a lawyer. Investors have the freedom to choose their own representation or opt to remain absent from the class and take no action at this point. This decision, however, does not affect their right to partake in any possible future reimbursement, should they remain passive and the court ultimately grant a recovery opportunity.

Counsel Transparency and Client Advocacy

The Rosen Law Firm positions itself as an advocate for transparency in legal proceedings and investor advocacy. The impact of a lawyer's history and track record cannot be overstated when contemplating representation in a securities class action. It is the staunch belief of the firm that they are equipped to provide the requisite experience, resources, and recognition to effectively champion the rights of investors around the globe.

The Rosen Law Firm's Commitment to Communication

Emphasizing open communication, The Rosen Law Firm actively updates interested parties on proceedings and other relevant information through various social media platforms, including LinkedIn, Twitter, and Facebook. Investors and the wider public are encouraged to follow these platforms for timely updates on the status of the Global Cord Blood Corporation class action and other cases handled by the firm.

Contact Information for Interested Parties

For more information or inquiries, interested parties may contact:

• Laurence Rosen, Esq.
• Phillip Kim, Esq.
• The Rosen Law Firm, P.A.
• 275 Madison Avenue, 40th Floor
• New York, NY 10016
• Tel: (212) 686-1060
• Toll Free: (866) 767-3653
• Fax: (212) 202-3827
• Email: [email protected]
• Website: www.rosenlegal.com

The firm's contact details are provided to ensure investors have ready access to the necessary resources to make an informed decision regarding their involvement in the class action suit.

Final Remarks and Disclaimer

This news article serves to inform the public and should not be perceived as a definitive outcome of the case. It is an attorney advertisement, and previous results secured by The Rosen Law Firm do not guarantee a similar outcome in future or current proceedings. Investors are encouraged to remain duly informed and to consider all legal avenues in the pursuit of justice and recovery of potential losses.

In conclusion, the class action lawsuit against Global Cord Blood Corporation marks a critical juncture for investors seeking to recover damages. With a well-respected law firm at the helm, individuals impacted by the alleged improprieties have a path to seek rectification for their financial losses. Investors are urged to pay heed to the approaching lead plaintiff deadline and to take action in line with their best interests.

This comprehensive outline and detailed information provide an essential resource to investors as they navigate the complexities of securities litigation. The Rosen Law Firm extends its hand in support, aiming to facilitate a fair and just legal process for all affected parties.